Cullen Capital Management LLC Acquires 36,714 Shares of Sanofi $SNY

Cullen Capital Management LLC raised its holdings in shares of Sanofi (NASDAQ:SNY) by 9.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 437,824 shares of the company’s stock after purchasing an additional 36,714 shares during the quarter. Cullen Capital Management LLC’s holdings in Sanofi were worth $21,151,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. lifted its stake in shares of Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares during the last quarter. OLD Mission Capital LLC bought a new position in Sanofi in the 1st quarter valued at about $48,938,000. Regal Partners Ltd lifted its position in Sanofi by 102.3% during the second quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock worth $74,794,000 after acquiring an additional 782,838 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Sanofi by 1,853.1% during the second quarter. NewEdge Advisors LLC now owns 731,208 shares of the company’s stock worth $35,325,000 after acquiring an additional 693,770 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Sanofi by 29.3% during the second quarter. American Century Companies Inc. now owns 1,959,185 shares of the company’s stock worth $94,648,000 after acquiring an additional 443,941 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 0.4%

Shares of NASDAQ SNY opened at $48.68 on Monday. The stock has a market capitalization of $119.53 billion, a P/E ratio of 11.40, a PEG ratio of 1.33 and a beta of 0.44. The stock’s fifty day moving average is $49.87 and its 200 day moving average is $49.02. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. The firm had revenue of $15.46 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.25 earnings per share. Sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $56.00 to $58.00 in a report on Monday, September 8th. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Sanofi in a report on Monday, December 1st. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.